Citigroup
IOVA icon

Citigroup’s Iovance Biotherapeutics IOVA Stock Holding History

Citigroup’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-50,000
Closed -$352K – 5724
2023
Q2 		$352K Sell
50,000
-40,000
-44% -$286K ﹤0.01% 3596
2023
Q1 		$550K Buy
+90,000
New +$621K ﹤0.01% 3064

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Citigroup's IOVA Position: Q1 2026 in Review

Citigroup reduced its Iovance Biotherapeutics (IOVA) stake by 23% in Q1 2026, selling an estimated $76.2K and leaving 81,725 shares worth $287K. The position accounts for ﹤0.01% of the portfolio, ranked #3816.

Citigroup first reported a position in IOVA in Q2 2015 and has held it in 44 quarters since. The position peaked at $8M in Q1 2024. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Citigroup held 81,725 shares of Iovance Biotherapeutics worth $287K as of Q1 2026.
  • Citigroup sold 23,815 Iovance Biotherapeutics shares in Q1 2026, an estimated $76.2K.
  • Iovance Biotherapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3816 holding.
  • Citigroup first reported a position in Iovance Biotherapeutics in Q2 2015 and has held it in 44 quarters since.
  • Citigroup's Iovance Biotherapeutics position peaked at $8M in Q1 2024.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.